Is BrainsWay Ltd. (BRSYF) a Buy, Sell, or Hold?
OTC : BRSYF
BrainsWay Ltd.
$15.13 USD
$0 (0.0%)
- Volume
- 300
- Average Volume
- 12
- Market Capitalization
- $607.19M
- P/E Ratio
- 67.96
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $16.84
- Year Low
- $5.49
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.34
Company Overview
OTC
Hadar Levy
Medical - Devices
Healthcare
BRSYF
129
IL
USD
Liquidity Metrics
0.09
3.34
3.04
2.49
0.00
Sales & Valuation
$56.53M
10.15
7.71
54.85
0.29
Profitability
$0.2
$8.26M
14.57%
15.68%
12.28%
7.54%
P/E Metrics
67.96
0.74
0.74
Analyst Price Target & Rating
3/5
4 Analysts
%
Financial Health Scores
9.12
5/9
$55.07M
$117M
$41.2M
$10.39M
Key Metrics (TTM)
$574.48M
9.49
78.76
3.34
12.28%
6.43%
1.48%
1.79%
$3.21
148 days
Company Executives
| Name | Title |
|---|---|
| Dor Hagai | Vice President of Operations |
| Hadar Levy | Chief Executive Officer |
| Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director |
| Colleen Hanlon | Vice President of Medical Affairs |
| David Zacut | Co-Founder & Vice-Chairman |
| Yiftach Roth | Founder & Chief Scientific Officer |
| Gilead Moiseyev | Chief Technology Officer |
| Menachem C. Klein | Vice President, General Counsel & Corporate Secretary |
| Michael Cohen | Vice President of US Sales |
| Ido Marom | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About BrainsWay Ltd. (OTC:BRSYF) Stock
BrainsWay Ltd. is a global medical technology company focused on innovating and providing non-invasive neurostimulation therapies for a broad spectrum of mental health and neurological conditions. Operating across the United States, Europe, Israel, and other international markets, the company's core offering is its Deep Transcranial Magnetic Stimulation (dTMS) platform. This advanced technology is employed in the treatment of numerous disorders, including severe depression, anxious depression, obsessive-compulsive disorder, smoking addiction, bipolar disorders, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatrists, hospita ... ls, and specialized medical centers. The company was established in 2003 and has its headquarters situated in Jerusalem, Israel.
2026-06-22 07:30:00
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients.
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript
2026-05-13 11:20:48
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current BrainsWay Ltd. (BRSYF) stock price?
-
BrainsWay Ltd.(OTC:BRSYF) stock price is $15.13 in the last trading session. During the trading session, BRSYF stock reached the peak price of $16.84 while $5.49 was the lowest point it dropped to. The percentage change in BRSYF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BRSYF stock was $0.
-
BRSYF's industry and sector of operation?
-
The OTC listed BRSYF is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of BRSYF?
-
Dor Hagai | Vice President of Operations
Hadar Levy | Chief Executive Officer
Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director
Colleen Hanlon | Vice President of Medical Affairs
David Zacut | Co-Founder & Vice-Chairman -
How many employees does BRSYF have?
-
Number of BRSYF employees currently stands at 129. BRSYF operates from Bynet Building, Jerusalem, JM 9777518, IL.
-
Link for BRSYF official website?
-
Official Website of BRSYF is: https://www.brainsway.com
-
How do I contact BRSYF?
-
BRSYF could be contacted at phone #972 2 582 4030 and can also be accessed through its website. BRSYF operates from Bynet Building, Jerusalem, JM 9777518, IL.
-
How many shares of BRSYF are traded daily?
-
The average number of BRSYF shares traded daily for last 3 months was 12.
-
What is the market cap of BRSYF currently?
-
The market value of BRSYF currently stands at $607.19M with its latest stock price at $15.13